Quantitative Clinical Rheumatology: Why Is a Test for Anti-CCP Antibodies Included in Most Routine Care for Rheumatoid Arthritis While a HAQ/MDHAQ Remains Largely a Research Tool?

Quantitative assessment of rheumatoid arthritis (RA) has been greatly advanced over the last few decades by important new measures. In 1980, the Health Assessment Questionnaire (HAQ) was reported by Fries and colleagues¹. Eighteen years later, anti-cyclic citrullinated peptides (anti-CCP) in RA were reported by Schellekens and colleagues².

Since 1980, the HAQ has been incorporated to provide 3 of the 7 Core Data Set measures for RA³, physical function, pain, and patient global estimate. The HAQ has been adapted for usual care as a modified HAQ (MHAQ), HAQ II, and multidimensional HAQ (MDHAQ)⁴. A HAQ/MDHAQ physical function score predicts severe longterm RA outcomes of work disability and premature mortality over 5–20 years at far higher levels of significance than radiographic scores or laboratory tests⁵. RAPID3 (Routine Assessment of Patient Index Data) scores of 3 HAQ/MDHAQ self-report measures distinguish active from control treatments in clinical trials as sensitively as joint counts, laboratory tests, and Disease Activity Score (DAS)28⁶. RAPID3 is correlated significantly with DAS28 and the Clinical Disease Activity Index (CDAI) in clinical trials⁶ and clinical care⁷, and is informative in patients with all rheumatic diseases⁸.

Since 1999, anti-CCP has offered important insights into the pathogenesis, prognosis, and course of RA⁹ and has been adapted for usual care with a variety of kits^{10,11}. Anti-CCP provides a significantly higher hazard ratio than rheumatoid factor (RF) to identify people with early arthritis who will develop progressive disease^{9,11}. These ratios are based on greater specificity of 95% in a metaanalysis of 37 studies, compared to 85% in 50 studies of RF for RA¹¹. The pooled sensitivity for RA of anti-CCP for progressive inflammatory arthritis in 37 studies was 67%, compared to 69% for RF¹¹. Therefore, 67% of RA patients have anti-CCP¹¹. By contrast, 86% have an abnormal MDHAQ-RAPID3 score⁷.

A “false-negative” rate of 33% for anti-CCP is of considerable concern. Current practice suggests that all patients

who have possible RA should be treated with “tight” control of inflammation, guided by clinical measures, without regard to anti-CCP or any other antibody status¹². Evidence-based information to guide management of RA is not yet available based on anti-CCP.

Nonetheless, anti-CCP tests are included in routine care based on suggestions that: (1) anti-CCP positivity identifies a distinct subset of patients who should be “monitored more carefully”; (2) anti-CCP-positive patients respond better to methotrexate (MTX) than anti-CCP-negative patients; (3) anti-CCP status may be useful when making treatment decisions in poor responders to MTX; (4) anti-CCP-positive patients are less likely to be able to withdraw therapy^{9–11}.

While all of these statements appear valid, we ask: (1) Should anti-CCP-negative patients be monitored less carefully than anti-CCP-positive patients? (2) Should a CCP-negative patient not be treated with MTX? (3) How does anti-CCP status change decisions in poor responders to MTX? (4) How does a lower likelihood to withdraw from therapy affect clinical decisions?

At this time, the “gold standard” to interpret a positive anti-CCP test remains a history and joint examination by a rheumatologist or other experienced physician. Anti-CCP provides considerable information concerning pathogenesis and outcomes in patient *groups*, but may have limited utility in the clinical care of *individual* patients. While anti-CCP ultimately may provide evidence-based guidance for management of individual patients, such knowledge will emerge from research settings, rather than from routine clinical testing.

The above information may suggest that a HAQ/MDHAQ might be used in usual patient care by all rheumatologists, while anti-CCP might be used primarily in research settings to better understand the pathogenesis and course of RA. Paradoxically, anti-CCP has been incorporated by most rheumatologists into standard clinical care, while HAQ/MDHAQ remains used primarily in research settings¹³.

This situation may be explained in part by the apparent importance of anti-CCP to the pathogenesis and prognosis of RA. A biomedical model, the guiding paradigm of 20th century medicine¹⁴, regards “objective” laboratory data, such as anti-CCP test, as having considerably greater value in the clinic than “subjective” data from patients, such as a HAQ/MDHAQ. The biomedical model has been spectacularly successful in acute medical situations and in development of new therapies for chronic diseases, including RA. Nonetheless, as noted, severe outcomes of work disability, costs, and death are predicted far more significantly by a HAQ/MDHAQ than by radiographs or laboratory tests identified to date⁵, suggesting a need for a supplementary biopsychosocial model for RA¹⁵.

Some observers (including 2 of the authors) have suggested that any patient who is considered to be a candidate for an anti-CCP test might be given an “n of 1” trial of weekly low-dose MTX and/or low-dose prednisone (≤ 5 mg/day)¹⁶. This empirical approach is analogous to treatment of possible infections with antibiotics. Ironically, weekly low-dose MTX and low-dose prednisone (≤ 5 mg/day) have fewer adverse events than most, if not all, antibiotics (or antihypertensive, antidepressant agents, etc.)¹⁷. A response provides presumptive evidence of inflammatory arthritis or spontaneous remission. No response would lead to discontinuation in 1–3 months, and further diagnostic and therapeutic measures.

Both anti-CCP and HAQ/MDHAQ are important advances in quantitative measurement of RA. Further research concerning CCP will likely lead to advances regarding the pathogenesis, course, and treatment of RA that cannot be provided by a HAQ/MDHAQ. However, such advances also cannot be provided by anti-CCP tests in routine care. We suggest that rigorous statistical scientific analysis indicates that any rheumatologist who orders an anti-CCP test at this time should also include a HAQ/MDHAQ in clinical care.

THEODORE PINCUS, MD;

YUSUF YAZICI, MD,

New York University Hospital for Joint Diseases,
New York, New York;

MARTIN J. BERGMAN, MD,

Taylor Hospital,
Ridley Park, Pennsylvania, USA

Address reprint requests to Dr. T. Pincus, Division of Rheumatology, Room 1608, NYU Hospital for Joint Diseases, 301 East 17th Street, New York, NY 10003. E-mail: tedpincus@gmail.com

Supported in part by grants from the Jack C. Massey Foundation.

REFERENCES

1. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. *Arthritis Rheum* 1980;23:137-45.
2. Schellekens GA, de Jong BAW, van den Hoogen FJH, van de Putte LBA, van Venrooij WJ. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. *J Clin Invest* 1998;101:273-81.
3. Felson DT, Anderson JJ, Boers M, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. *Arthritis Rheum* 1993;36:729-40.
4. Pincus T, Sokka T, Kautiainen H. Further development of a physical function scale on a Multidimensional Health Assessment Questionnaire for standard care of patients with rheumatic diseases. *J Rheumatol* 2005;32:1432-9.
5. Pincus T, Sokka T. Quantitative measures to assess patients with rheumatic diseases: 2006 update. *Rheum Dis Clin North Am* 2006;32 Suppl:29-36.
6. Pincus T, Bergman MJ, Yazici Y, Hines P, Raghupathi K, Maclean R. An index of only patient-reported outcome measures, Routine Assessment of Patient Index Data 3 (RAPID3), in two abatacept clinical trials: similar results to Disease Activity Score (DAS28) and other RAPID indices that include physician-reported measures. *Rheumatology* 2008;47:345-9.
7. Pincus T, Swearingen CJ, Bergman M, Yazici Y. RAPID3 (Routine Assessment of Patient Index Data 3), a rheumatoid arthritis index without formal joint counts for routine care: Proposed severity categories compared to DAS and CDAI categories. *J Rheumatol* 2008;35:2136-47.
8. Pincus T, Sokka T. Can a Multi-Dimensional Health Assessment Questionnaire (MDHAQ) and Routine Assessment of Patient Index Data (RAPID) scores be informative in patients with all rheumatic diseases? *Best Pract Res Clin Rheumatol* 2007;21:733-53.
9. Huizinga TW, Amos CI, van der Helm-van Mil AHM, et al. Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA-DRB1 shared epitope for antibodies to citrullinated proteins. *Arthritis Rheum* 2005;52:3433-8.
10. Riedemann JP, Muñoz S, Kavanaugh A. The use of second generation anti-CCP antibody (anti-CCP2) testing in rheumatoid arthritis — a systematic review. *Clin Exp Rheumatol* 2005;23:S69-76.
11. Nishimura K, Sugiyama D, Kogata Y, et al. Meta-analysis: Diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. *Ann Intern Med* 2007;146:797-808.
12. Goekoop-Ruiterman YPM, de Vries-Bouwstra JK, Allaart CF, et al. Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. *Ann Intern Med* 2007;146:406-15.
13. Wolfe F, Pincus T, Thompson AK, Doyle J. The assessment of rheumatoid arthritis and the acceptability of self-report questionnaires in clinical practice. *Arthritis Care Res* 2003;49:59-63.
14. Engel GL. The need for a new medical model: a challenge for biomedicine. *Science* 1977;196:129-36.
15. Abelson B, Rupel A, Pincus T. Limitations of a biomedical model to explain socioeconomic disparities in mortality of rheumatic and cardiovascular diseases. *Clin Exp Rheumatol* 2008;26 Suppl:S25-34.
16. Pincus T, Huizinga TWJ, Yazici Y. N-of-1 trial of low-dose methotrexate and/or prednisolone in lieu of anti-CCP, MRI, or ultrasound, as first option in suspected rheumatoid arthritis? *J Rheumatol* 2007;34:250-2.
17. Yazici Y, Sokka T, Kautiainen H, Swearingen C, Kulman I, Pincus T. Long term safety of methotrexate in routine clinical care: discontinuation is unusual and rarely the result of laboratory abnormalities. *Ann Rheum Dis* 2005;64:207-11.

J Rheumatol 2009;36:1563–4; doi:10.3899/jrheum.080563